Journal article
Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry
R Manchanda, S Patel, AC Antoniou, E Levy-Lahad, C Turnbull, DG Evans, JL Hopper, RJ Macinnis, U Menon, I Jacobs, R Legood
American Journal of Obstetrics and Gynecology | MOSBY-ELSEVIER | Published : 2017
Abstract
Background Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with family history–based testing in Ashkenazi-Jewish women were >30 years old with 4 Ashkenazi-Jewish grandparents. However, individuals may have 1, 2, or 3 Ashkenazi-Jewish grandparents, and cost-effectiveness data are lacking at these lower BRCA prevalence estimates. We present an updated cost-effectiveness analysis of population BRCA1/BRCA2 testing for women with 1, 2, and 3 Ashkenazi-Jewish grandparents. Study Design Decision analysis model. Methods Lifetime costs and effects of population and family history–based testing were compared with the use of a decision analysis model. 56% BRCA carriers..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Supported by "The Eve Appeal" charity, which had no role in the study design, data collection, analysis, interpretation, writing of the report, or decision to submit for publication. The research team was independent of funders. I.J. and U.M. have a financial interest in Abcodia, Ltd, which is a company formed to develop academic and commercial development of biomarkers for screening and risk prediction; I.J. is a member of the board of Abcodia Ltd and a Director of Women's Health Specialists Ltd. R.M. declares funding for research from Cancer Research UK and Barts and the London Charity outside this submitted work and an honorarium for grant review from Israel National institute for Health Policy Research. The other authors declare no conflict of interest.